<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007434</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-101-13-36</org_study_id>
    <nct_id>NCT02007434</nct_id>
  </id_info>
  <brief_title>Patient Experience Study of Deoxycholic Acid Injection</brief_title>
  <official_title>A Single Center, Double-blind, Parallel-group, Two Factor Patient-Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine the safety of deoxycholic acid subcutaneous
      (SC) injections in the submental area and to evaluate the effects of four interventions,
      relative to placebo in the submental area, particularly with regard to assessment and
      management of pain, bruising, and swelling/edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the effects of four interventions, pre- and post-subcutaneous injections
      of deoxycholic acid injection relative to placebo in adults with submental fullness.
      Participants were randomized to either deoxycholic acid injection or placebo in a ratio of
      4:1 and to one of four patient experience management paradigms.

      Participants were required to visit the research facility on 10 separate occasions for
      protocol-defined treatments, procedures, tests, and observations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Pain Visual Analog Scale Scores</measure>
    <time_frame>Baseline and Day 84</time_frame>
    <description>Participants were provided with a scale 100 mm in length and were asked to mark the place on the line that best represents his or her pain associated with the area treated with study drug. The scale ranged from 0 (no pain) to 100 (most severe pain possible).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pain Assessment Using McGill Pain Questionnaire</measure>
    <time_frame>Baseline (predose) and Day 84</time_frame>
    <description>Participants rated 15 pain characteristics by using a number to signify how much of that specific type of pain they were experiencing using the Short-Form McGill Pain Questionnaire. The pain characteristic options included Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, and Punishing- cruel. Participants assessed the intensity of each characteristic using the following score system: none (0), mild (1), moderate (2), and severe (3). In addition, present pain was assessed on a scale from 0 (no pain) to 5 (excruciating).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swelling Grading Scale Scores</measure>
    <time_frame>Day 84</time_frame>
    <description>The following grading system was used for the assessment of swelling:
Swelling/edema absent (0)
Minimal swelling/edema contained within treatment area (1)
Modest swelling/edema contained within treatment area (2)
Substantial swelling/edema contained within treatment area (3)
Swelling/edema of the neck and face beyond the treatment area (4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bruising Grading Scale Scores</measure>
    <time_frame>Day 84</time_frame>
    <description>The following grading system was used for the assessment of bruising:
Bruising absent (0)
Bruising associated with 1 to 3 needle insertion points (1)
Bruising spreading beyond 4 or more individual needle insertion points but contained within the treatment area (2)
Bruising covering the entire treatment area but contained within the treatment area (3)
Bruising of the neck and face beyond the treatment area (4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Induration Grading Scale Scores</measure>
    <time_frame>Day 84</time_frame>
    <description>The following grading system was used for the assessment of induration:
Induration absent to minimal (0)
Induration associated with at least approximately 30% of the treatment area (1)
Induration associated with greater than approximately 30% to at least 60% of the treatment area (2)
Induration covering the entire treatment area but contained within the treatment area (3)
Induration of the neck and face beyond the treatment area (4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</measure>
    <time_frame>Baseline and Day 84</time_frame>
    <description>The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</measure>
    <time_frame>Baseline and Day 84</time_frame>
    <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Subject Self Rating Scale (SSRS)</measure>
    <time_frame>Baseline and Day 84</time_frame>
    <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Submental Skin Laxity Grades (SMSLG)</measure>
    <time_frame>Baseline and Day 84</time_frame>
    <description>Skin laxity assessment was based on clinical evaluation and palpation of the submental area on the following scale: 1 = no laxity; 2 = mild laxity; 3 = moderate laxity; 4 = severe laxity. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Submental Fat Thickness</measure>
    <time_frame>Baseline and Day 84</time_frame>
    <description>Submental thickness was measured using caliper devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Experience Questions</measure>
    <time_frame>Day 84</time_frame>
    <description>Participants were asked to complete 3 patient experience questions, each answered as Yes or No:
Given your experience in this study:
Would you recommend this procedure to a friend?
Would you agree to receive additional treatments?
Has the treatment you received in this study affected your normal activities?
The percentage of participants answering Yes on each question is reported.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Moderate or Severe Submental Fullness</condition>
  <arm_group>
    <arm_group_label>Paradigm 1 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 1/ Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 2 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 2 / Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 3 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 3 / Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deoxycholic Acid Injection</intervention_name>
    <description>Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.</description>
    <arm_group_label>Paradigm 1 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 2 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 3 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <other_name>ATX-101</other_name>
    <other_name>Kybella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate buffered saline placebo for injection</description>
    <arm_group_label>Paradigm 1/ Placebo</arm_group_label>
    <arm_group_label>Paradigm 2 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 3 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Compress</intervention_name>
    <description>A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.</description>
    <arm_group_label>Paradigm 1 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 1/ Placebo</arm_group_label>
    <arm_group_label>Paradigm 2 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 2 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 3 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 3 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine / Epinephrine</intervention_name>
    <description>Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.</description>
    <arm_group_label>Paradigm 2 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 2 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 3 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 3 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>Loratadine 10 mg orally from Day -7 until Day 7</description>
    <arm_group_label>Paradigm 3 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 3 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.</description>
    <arm_group_label>Paradigm 3 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 3 / Placebo</arm_group_label>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compression Chin Strap</intervention_name>
    <description>A compression chin strap was applied 15 minutes after dosing for at least 24 hours.</description>
    <arm_group_label>Paradigm 4 / Deoxycholic Acid Injection</arm_group_label>
    <arm_group_label>Paradigm 4 / Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Submental fat graded by the Investigator as 2 (moderate) or 3 (severe) using the
             Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and graded by the subject as
             2 (moderate amount) or 3 (large amount) using the Patient-Reported Submental Fat
             Rating Scale (PR-SMFRS)

          2. Dissatisfaction with the appearance of the submental area expressed by the subject as
             a rating of 0, 1, or 2 using the Subject Self Rating Scale (SSRS)

          3. History of stable body weight for at least 6 months and body mass index (BMI) of ≤ 40
             kg/m².

          4. Acceptable skin laxity as determined by the investigator

          5. Agreement by the subject to refrain from making significant changes, in the documented
             judgment of the investigator, to his or her dietary or exercise habits during the
             course of the subject's participation.

          6. Agreement to forego any treatment or behavior (e.g., unshaven facial hair)

          7. Signed informed consent obtained before any study-specific procedure is performed.

        Exclusion Criteria:

          1. No prior intervention for submental fullness or recent cosmetic procedure in the neck
             or chin area

          2. Absence of clinically significant health problems

          3. Body mass index &gt; 40.0 kg/m² as determined prior to randomization.

          4. History of drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Beddingfield, III, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>June 12, 2015</results_first_submitted>
  <results_first_submitted_qc>June 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2015</results_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was performed at one investigational center in the United States (US).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Paradigm 1 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline Clinician-Reported Submental Fat Rating Scale [CR-SMFRS] grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P2">
          <title>Paradigm 1 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P3">
          <title>Paradigm 2 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P4">
          <title>Paradigm 2 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P5">
          <title>Paradigm 3 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P6">
          <title>Paradigm 3 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P7">
          <title>Paradigm 4 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="P8">
          <title>Paradigm 4 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set</population>
      <group_list>
        <group group_id="B1">
          <title>Paradigm 1 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B2">
          <title>Paradigm 1 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B3">
          <title>Paradigm 2 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B4">
          <title>Paradigm 2 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B5">
          <title>Paradigm 3 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B6">
          <title>Paradigm 3 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B7">
          <title>Paradigm 4 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B8">
          <title>Paradigm 4 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="16"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="18"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="11.08"/>
                    <measurement group_id="B2" value="36.3" spread="14.05"/>
                    <measurement group_id="B3" value="42.4" spread="13.08"/>
                    <measurement group_id="B4" value="43.8" spread="11.67"/>
                    <measurement group_id="B5" value="41.3" spread="11.48"/>
                    <measurement group_id="B6" value="44.8" spread="14.84"/>
                    <measurement group_id="B7" value="42.3" spread="13.08"/>
                    <measurement group_id="B8" value="48.0" spread="8.64"/>
                    <measurement group_id="B9" value="43.5" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191.01" spread="40.086"/>
                    <measurement group_id="B2" value="221.00" spread="34.492"/>
                    <measurement group_id="B3" value="205.61" spread="38.716"/>
                    <measurement group_id="B4" value="223.90" spread="27.534"/>
                    <measurement group_id="B5" value="205.74" spread="32.847"/>
                    <measurement group_id="B6" value="217.90" spread="11.485"/>
                    <measurement group_id="B7" value="200.30" spread="36.592"/>
                    <measurement group_id="B8" value="185.05" spread="68.356"/>
                    <measurement group_id="B9" value="202.53" spread="37.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.959" spread="4.2723"/>
                    <measurement group_id="B2" value="28.867" spread="4.9923"/>
                    <measurement group_id="B3" value="33.206" spread="4.9806"/>
                    <measurement group_id="B4" value="33.350" spread="3.1586"/>
                    <measurement group_id="B5" value="32.763" spread="3.7764"/>
                    <measurement group_id="B6" value="36.850" spread="2.3587"/>
                    <measurement group_id="B7" value="31.706" spread="3.3457"/>
                    <measurement group_id="B8" value="31.250" spread="7.7229"/>
                    <measurement group_id="B9" value="32.266" spread="4.3474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Fitzpatrick Skin Type is a numerical classification schema for human skin color and typical response to ultraviolet (UV) light:
Type I: Pale white skin, blue/hazel eyes, blond/red hair; Always burns, does not tan.
Type II: Fair skin, blue eyes; Burns easily, tans poorly.
Type III: Darker white skin; Tans after initial burn.
Type IV: Light brown skin; Burns minimally, tans easily.
Type V: Brown skin; Rarely burns, tans darkly easily.
Type VI: Dark brown or black skin; Never burns, always tans darkly.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I-III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV-VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</title>
          <description>The CR-SMFRS score is based on the investigator’s clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0–4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</title>
          <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0–4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subject Self Rating Scale (SSRS)</title>
          <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pain Visual Analog Scale Scores</title>
        <description>Participants were provided with a scale 100 mm in length and were asked to mark the place on the line that best represents his or her pain associated with the area treated with study drug. The scale ranged from 0 (no pain) to 100 (most severe pain possible).</description>
        <time_frame>Baseline and Day 84</time_frame>
        <population>Safety analysis set with available data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Visual Analog Scale Scores</title>
          <description>Participants were provided with a scale 100 mm in length and were asked to mark the place on the line that best represents his or her pain associated with the area treated with study drug. The scale ranged from 0 (no pain) to 100 (most severe pain possible).</description>
          <population>Safety analysis set with available data at both time points</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O7" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O8" value="0.0" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise differences between paradigms for the placebo-adjusted differences were conducted using a two-way analysis of covariance (ANCOVA) with factors for treatment, paradigm, treatment-by-paradigm interaction, and covariate of baseline CR-SMFRS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6803</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Placebo-adjusted Difference</param_type>
            <param_value>0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.59</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>Paradigm 1 - Paradigm 2</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Day 0, 1 Minute. Pairwise differences between paradigms for the placebo-adjusted differences were conducted using a two-way analysis of covariance (ANCOVA) with factors for treatment, paradigm, treatment-by-paradigm interaction, and covariate of baseline CR-SMFRS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5206</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Placebo-adjusted Difference</param_type>
            <param_value>0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>Paradigm 1 - Paradigm 3</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Pairwise differences between paradigms for the placebo-adjusted differences were conducted using a two-way analysis of covariance (ANCOVA) with factors for treatment, paradigm, treatment-by-paradigm interaction, and covariate of baseline CR-SMFRS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6060</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Placebo-adjusted Difference</param_type>
            <param_value>0.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.58</dispersion_value>
            <ci_percent>395</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>Paradigm 1 - Paradigm 4</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Pairwise differences between paradigms for the placebo-adjusted differences were conducted using a two-way analysis of covariance (ANCOVA) with factors for treatment, paradigm, treatment-by-paradigm interaction, and covariate of baseline CR-SMFRS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7935</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Placebo-adjusted Difference</param_type>
            <param_value>0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Paradigm 2 - Paradigm 3</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Pairwise differences between paradigms for the placebo-adjusted differences were conducted using a two-way analysis of covariance (ANCOVA) with factors for treatment, paradigm, treatment-by-paradigm interaction, and covariate of baseline CR-SMFRS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9140</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Placebo-adjusted Difference</param_type>
            <param_value>0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Paradigm 2 - Paradigm 4</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Pairwise differences between paradigms for the placebo-adjusted differences were conducted using a two-way analysis of covariance (ANCOVA) with factors for treatment, paradigm, treatment-by-paradigm interaction, and covariate of baseline CR-SMFRS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8754</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Placebo-adjusted Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Paradigm 3 - Paradigm 4</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pain Assessment Using McGill Pain Questionnaire</title>
        <description>Participants rated 15 pain characteristics by using a number to signify how much of that specific type of pain they were experiencing using the Short-Form McGill Pain Questionnaire. The pain characteristic options included Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, and Punishing- cruel. Participants assessed the intensity of each characteristic using the following score system: none (0), mild (1), moderate (2), and severe (3). In addition, present pain was assessed on a scale from 0 (no pain) to 5 (excruciating).</description>
        <time_frame>Baseline (predose) and Day 84</time_frame>
        <population>Safety analysis set with available data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 to 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Assessment Using McGill Pain Questionnaire</title>
          <description>Participants rated 15 pain characteristics by using a number to signify how much of that specific type of pain they were experiencing using the Short-Form McGill Pain Questionnaire. The pain characteristic options included Throbbing, Shooting, Stabbing, Sharp, Cramping, Gnawing, Hot-burning, Aching, Heavy, Tender, Splitting, Tiring-exhausting, Sickening, Fearful, and Punishing- cruel. Participants assessed the intensity of each characteristic using the following score system: none (0), mild (1), moderate (2), and severe (3). In addition, present pain was assessed on a scale from 0 (no pain) to 5 (excruciating).</description>
          <population>Safety analysis set with available data at both time points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Throbbing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shooting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stabbing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sharp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cramping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gnawing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hot-Burning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.1" spread="0.25"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heavy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.1" spread="0.25"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tender</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.1" spread="0.25"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.1" spread="0.25"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Splitting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiring-Exhausting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sickening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fearful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Punishing-Cruel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Swelling Grading Scale Scores</title>
        <description>The following grading system was used for the assessment of swelling:
Swelling/edema absent (0)
Minimal swelling/edema contained within treatment area (1)
Modest swelling/edema contained within treatment area (2)
Substantial swelling/edema contained within treatment area (3)
Swelling/edema of the neck and face beyond the treatment area (4)</description>
        <time_frame>Day 84</time_frame>
        <population>Safety analysis set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Swelling Grading Scale Scores</title>
          <description>The following grading system was used for the assessment of swelling:
Swelling/edema absent (0)
Minimal swelling/edema contained within treatment area (1)
Modest swelling/edema contained within treatment area (2)
Substantial swelling/edema contained within treatment area (3)
Swelling/edema of the neck and face beyond the treatment area (4)</description>
          <population>Safety analysis set with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bruising Grading Scale Scores</title>
        <description>The following grading system was used for the assessment of bruising:
Bruising absent (0)
Bruising associated with 1 to 3 needle insertion points (1)
Bruising spreading beyond 4 or more individual needle insertion points but contained within the treatment area (2)
Bruising covering the entire treatment area but contained within the treatment area (3)
Bruising of the neck and face beyond the treatment area (4)</description>
        <time_frame>Day 84</time_frame>
        <population>Safety analysis set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Bruising Grading Scale Scores</title>
          <description>The following grading system was used for the assessment of bruising:
Bruising absent (0)
Bruising associated with 1 to 3 needle insertion points (1)
Bruising spreading beyond 4 or more individual needle insertion points but contained within the treatment area (2)
Bruising covering the entire treatment area but contained within the treatment area (3)
Bruising of the neck and face beyond the treatment area (4)</description>
          <population>Safety analysis set with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.0" spread="0.00"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Induration Grading Scale Scores</title>
        <description>The following grading system was used for the assessment of induration:
Induration absent to minimal (0)
Induration associated with at least approximately 30% of the treatment area (1)
Induration associated with greater than approximately 30% to at least 60% of the treatment area (2)
Induration covering the entire treatment area but contained within the treatment area (3)
Induration of the neck and face beyond the treatment area (4)</description>
        <time_frame>Day 84</time_frame>
        <population>Safety analysis set with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Induration Grading Scale Scores</title>
          <description>The following grading system was used for the assessment of induration:
Induration absent to minimal (0)
Induration associated with at least approximately 30% of the treatment area (1)
Induration associated with greater than approximately 30% to at least 60% of the treatment area (2)
Induration covering the entire treatment area but contained within the treatment area (3)
Induration of the neck and face beyond the treatment area (4)</description>
          <population>Safety analysis set with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.1" spread="0.25"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                    <measurement group_id="O5" value="0.0" spread="0.00"/>
                    <measurement group_id="O6" value="0.0" spread="0.00"/>
                    <measurement group_id="O7" value="0.1" spread="0.32"/>
                    <measurement group_id="O8" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</title>
        <description>The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Day 84</time_frame>
        <population>Safety analysis set with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)</title>
          <description>The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement.</description>
          <population>Safety analysis set with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.50"/>
                    <measurement group_id="O2" value="-0.7" spread="0.58"/>
                    <measurement group_id="O3" value="-0.6" spread="0.63"/>
                    <measurement group_id="O4" value="-0.8" spread="0.96"/>
                    <measurement group_id="O5" value="-0.4" spread="0.50"/>
                    <measurement group_id="O6" value="0.0" spread="0.82"/>
                    <measurement group_id="O7" value="-0.4" spread="0.50"/>
                    <measurement group_id="O8" value="-0.3" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</title>
        <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Day 84</time_frame>
        <population>Safety analysis set with available data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)</title>
          <description>The PR-SMFRS is based on the participant's response to the question &quot;How much fat do you have under your chin right now?&quot; answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. A negative change from Baseline indicates improvement.</description>
          <population>Safety analysis set with available data at both time points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.75"/>
                    <measurement group_id="O2" value="-0.7" spread="1.15"/>
                    <measurement group_id="O3" value="-0.9" spread="0.72"/>
                    <measurement group_id="O4" value="-0.5" spread="1.29"/>
                    <measurement group_id="O5" value="-0.8" spread="0.86"/>
                    <measurement group_id="O6" value="-0.8" spread="0.50"/>
                    <measurement group_id="O7" value="-0.7" spread="0.57"/>
                    <measurement group_id="O8" value="-0.5" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Subject Self Rating Scale (SSRS)</title>
        <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Day 84</time_frame>
        <population>Safety analysis set with available data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Subject Self Rating Scale (SSRS)</title>
          <description>The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement.</description>
          <population>Safety analysis set with available data at both time points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.84"/>
                    <measurement group_id="O2" value="2.3" spread="3.51"/>
                    <measurement group_id="O3" value="3.2" spread="1.56"/>
                    <measurement group_id="O4" value="1.8" spread="1.71"/>
                    <measurement group_id="O5" value="2.3" spread="1.95"/>
                    <measurement group_id="O6" value="2.3" spread="1.50"/>
                    <measurement group_id="O7" value="2.4" spread="1.38"/>
                    <measurement group_id="O8" value="2.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Submental Skin Laxity Grades (SMSLG)</title>
        <description>Skin laxity assessment was based on clinical evaluation and palpation of the submental area on the following scale: 1 = no laxity; 2 = mild laxity; 3 = moderate laxity; 4 = severe laxity. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline and Day 84</time_frame>
        <population>Safety analysis set with available data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Submental Skin Laxity Grades (SMSLG)</title>
          <description>Skin laxity assessment was based on clinical evaluation and palpation of the submental area on the following scale: 1 = no laxity; 2 = mild laxity; 3 = moderate laxity; 4 = severe laxity. A negative change from Baseline indicates improvement.</description>
          <population>Safety analysis set with available data at both time points</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.66"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.1" spread="0.77"/>
                    <measurement group_id="O4" value="0.5" spread="0.58"/>
                    <measurement group_id="O5" value="0.3" spread="0.45"/>
                    <measurement group_id="O6" value="0.5" spread="0.58"/>
                    <measurement group_id="O7" value="0.3" spread="0.67"/>
                    <measurement group_id="O8" value="0.3" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Submental Fat Thickness</title>
        <description>Submental thickness was measured using caliper devices.</description>
        <time_frame>Baseline and Day 84</time_frame>
        <population>Safety analysis set with available data at both time points</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Submental Fat Thickness</title>
          <description>Submental thickness was measured using caliper devices.</description>
          <population>Safety analysis set with available data at both time points</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.67"/>
                    <measurement group_id="O2" value="-2.3" spread="2.08"/>
                    <measurement group_id="O3" value="-1.6" spread="2.34"/>
                    <measurement group_id="O4" value="-0.3" spread="2.75"/>
                    <measurement group_id="O5" value="-0.9" spread="3.77"/>
                    <measurement group_id="O6" value="-2.3" spread="2.22"/>
                    <measurement group_id="O7" value="-1.5" spread="3.33"/>
                    <measurement group_id="O8" value="-2.8" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Experience Questions</title>
        <description>Participants were asked to complete 3 patient experience questions, each answered as Yes or No:
Given your experience in this study:
Would you recommend this procedure to a friend?
Would you agree to receive additional treatments?
Has the treatment you received in this study affected your normal activities?
The percentage of participants answering Yes on each question is reported.</description>
        <time_frame>Day 84</time_frame>
        <population>Safety analysis set with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Paradigm 1 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O2">
            <title>Paradigm 1 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O3">
            <title>Paradigm 2 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O4">
            <title>Paradigm 2 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O5">
            <title>Paradigm 3 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O6">
            <title>Paradigm 3 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O7">
            <title>Paradigm 4 / Deoxycholic Acid Injection</title>
            <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
          <group group_id="O8">
            <title>Paradigm 4 / Placebo</title>
            <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Experience Questions</title>
          <description>Participants were asked to complete 3 patient experience questions, each answered as Yes or No:
Given your experience in this study:
Would you recommend this procedure to a friend?
Would you agree to receive additional treatments?
Has the treatment you received in this study affected your normal activities?
The percentage of participants answering Yes on each question is reported.</description>
          <population>Safety analysis set with available data at each time point</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="16"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recommend to a Friend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="72"/>
                    <measurement group_id="O8" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Receive Additional Treatments</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="88"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="78"/>
                    <measurement group_id="O8" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal Activity Affected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Paradigm 1 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E2">
          <title>Paradigm 1 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E3">
          <title>Paradigm 2 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E4">
          <title>Paradigm 2 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E5">
          <title>Paradigm 3 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E6">
          <title>Paradigm 3 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E7">
          <title>Paradigm 4 / Deoxycholic Acid Injection</title>
          <description>Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
        <group group_id="E8">
          <title>Paradigm 4 / Placebo</title>
          <description>Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site nodule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Skin tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Study Agreement requires that the investigator or institution obtain written consent from Kythera prior to presenting and/or publishing results of this study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Kythera</organization>
      <email>clinical_trials@kythera.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

